Drug intelligence / Profile preview

bacterial consortium CRC

Development stage: Preclinical
Lead developer: PharmaBiome
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Colon Infusion, Intracolonic, Colonoscopy (intracolonic)

Overview

PharmaBiome's bacterial consortium for colorectal cancer (CRC) is a preclinical-stage live biotherapeutic product (LBP) consisting of a rationally assembled group of bacterial strains. Developed using the company's proprietary Niche-Map technology, the consortium is designed to restore specific microbiome functionalities that are disrupted in colorectal cancer biology. By co-culturing these strains in bioreactors, PharmaBiome aims to create a standardized, defined alternative to fecal microbiota transplantation (FMT) that can modulate the gut environment to inhibit tumor progression or enhance the efficacy of other treatments. The program is currently in the preclinical stage of development.

Other names: Bacterial Consortium (CRC)PharmaBiome CRC program

Beyond the preview

Go deeper on bacterial consortium CRC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bacterial consortium CRC.

Explore the full profile